Published on: September 15, 2026
Something has shifted in aesthetic medicine, and the numbers back it up. U.S. spending on facial filler fell from roughly $970 million to about $850 million per quarter between 2023 and 2025, according to the healthcare data firm Guidepoint Qsight. Juvéderm, one of the most recognized hyaluronic acid fillers on the market, saw its global revenue drop 15% in 2025 — enough to knock it out of billion-dollar-product status. Over that same period, spending on facial surgery climbed 22% in the first half of 2026 alone. Filler isn't disappearing. But the instant-plump version of it, the kind that inflates a face rather than restoring it, is losing ground. As someone who has been saying this for years, I think that's a welcome correction.
I covered this shift in detail on a recent episode of my podcast, Medspa Confidential, called "The Great Deflate: What's Really Behind America's Filler Backlash." What struck me putting that episode together wasn't just that filler sales are down. It's what's happening underneath that number: the decline isn't uniform. Instant-plump HA fillers are down 18% since 2023, while collagen-stimulating treatments like Sculptra are actually growing. People aren't necessarily walking away from injectables. They're walking away from volume for volume's sake, and moving toward treatments that build something that lasts.
A few forces are converging here. GLP-1 medications have shifted the country's weight, and the aesthetic ideal has shifted with it toward a thinner, more natural look that doesn't pair well with an overfilled face — even as more patients develop real facial hollowing from rapid weight loss and technically need volume restored. Public sentiment has turned, too: several well-known actresses have spoken openly about regretting filler and how hard it is to reverse years later. And the industry itself is playing defense: one company is now urging providers to stop using the word "filler" in favor of "hyaluronic acid gel," and a major manufacturer has been out describing a syringe of its product as "the size of a blueberry." When an industry pivots to renaming its own product, that tells you something about how much the underlying concern has caught on.
None of this means filler is unsafe when it's used correctly. Hyaluronic acid filler has a well-established safety profile and, in most cases, can be dissolved — part of why it became so popular in the first place. But a few things deserve more attention than they typically get: filler doesn't always fully clear from tissue even after it's "dissolved," and vascular occlusion, while rare, remains a serious complication that can affect the face and vision. That belongs in informed consent, not in the fine print. The clinical problem was never the product. It was volume used as the only tool, in place of an actual treatment plan.
Once you're past your mid-twenties, collagen production declines by roughly one percent a year, and elastin follows a similar downward curve. The result is thinner, looser, more droopy skin. That decline, not a lack of filler, is what actually changes a face over time. Filler adds material on top of that process. It doesn't slow it down. A biostimulatory treatment does something different: it triggers the body to manufacture its own collagen, over months, in tissue that keeps that structure after the treatment course ends. I've called Sculptra the "opposite filler" for exactly that reason — you're building a permanent structure instead of renting temporary volume.
At Glow, this is where most of our collagen-focused work lives. RF microneedling (we use the Genius RF platform) combines controlled micro-injury with radiofrequency energy to rebuild collagen and elastin, and works particularly well for jawline and neck laxity. PRP with microneedling, layering a patient's own growth factors into the treatment, is the gentlest entry point with the least downtime. EMFACE pairs needle-free radiofrequency with muscle stimulation for a collagen and muscle-lift effect with zero downtime. For crepiness or textural damage, laser resurfacing with LaseMD Ultra remains one of our more reliable tools. Sculptra still has a place on this list, used sparingly and as a complement to structural treatments rather than a first move.
A series of in-office treatments, however good the technology, is still not a substitute for what happens on a patient's skin every day. Medical-grade skincare — retinoids, antioxidants, growth-factor serums, and a real barrier-repair routine — maintains the skin over years in a way that maximizes results from any single or series of procedures. In-office maintenance, including chemical peels, HydraFacial, dermaplaning, and BBL/IPL photorejuvenation, also supports that daily foundation. The research on skin aging is consistent on this point: outcomes track with years of consistent care, not with any single intervention.
Sun protection remains the single most evidence-supported intervention against visible skin aging — the majority of what we call photoaging is, by definition, sun damage, and it is also the primary modifiable risk factor for skin cancer. Daily broad-spectrum SPF does more for how skin looks in twenty years than almost anything applied afterward. It also belongs in the same conversation as cancer prevention. Long-term skin health has to include that vigilance, or it isn't actually long-term.
Related blog post: Why Modern Sun Protection Is Shifting Beyond "SPF Only"
Skin doesn't age in isolation from the rest of the body. Maintaining a stable, healthy weight, regular exercise, a diet that controls chronic inflammation and blood sugar, and adequate sleep all show up in skin quality, because collagen synthesis and skin repair are metabolically expensive processes that compete with the rest of what the body has to do. Hormonal shifts, particularly through perimenopause and menopause, accelerate collagen loss independent of chronological age, which is part of why we built our GlowBalance program to address hormonal and systemic contributors to skin aging rather than treating skin as a problem that exists on its own. The GLP-1 story is a useful illustration of the same principle in reverse: rapid, significant weight loss can produce real facial hollowing, which is a reminder that whatever a patient does for their overall health has direct, visible consequences on their face.
The wellness and longevity movements dominating dinner-table conversation and social media right now are, at their core, making the argument I've been making in practice for a long time: that looking well is downstream of being well, and that durable results come from process, not from a single procedure. The backlash against the overfilled look the Wall Street Journal has been calling "heroin chic" is really a backlash against treating the face as a problem to solve instantly rather than a structure to maintain over decades. That's a healthier framework, and it happens to be the one Glow Medispa was built around from the start: build the skin's own structure, protect it, support it systemically, and let the results compound. That approach was never trendy. It's good to see the culture catch up to it.
Dr. Kate Dee is the founder of Glow Medispa in West Seattle and Kirkland. She is a Yale-trained physician with a deep interest in skin health, hormones, and medical aesthetics.
